top of page

Technology

Pavaka is a medical device company developing an investigational electroceutical wound dressing. Unlike passive dressings, the Pavaka dressing is actively powered by an onboard battery, so the field it generates can be set by design.
From Ohio State research to a manufacturable device on a path to FDA clearance.


A powered, patterned dressing

The investigational dressing generates a low-level electric field at the wound surface. Its architecture combines printed electrodes, a flexible dressing and a power source.

​​

The research program examines how operating conditions, electrode geometry and the wound environment affect dressing performance. The dressing is investigational and is not available for sale.

Pavaka investigational dressing (Gen 1). Not a cleared or approved product.

From pattern to applied field

Printed anode and cathode patterns connect to an onboard battery through a current-limiting circuit, and a flexible substrate forms the dressing.

​

Each study on this site names the device version it used.

Why we measure more than one signal

Bioluminescence (metabolism)

Reporter activity in a controlled bacterial model is not a diagnosis or proof of sterilization.

Culture (viability)

Recoverable bacteria in a sampled region do not describe an entire wound.

Microscopy (structure)

Local cellular changes add context but cannot replace biological or clinical endpoints.

bench-electrical-testing.jpg

Pavaka bench photograph. Electrical testing is not evidence of clinical benefit.

From a hand-built research device to a design built for production

The dressing has gone through two generations. Gen 1 is the dressing used in clinical research to date. Gen 2 is a redesign of the same platform for scalable manufacturing. Both generate a low-level electric field at the wound surface.

​

Gen 1 · Used in clinical research

Gen 1 was used in an early clinical study published in 2019 and in the 112-patient randomized study (NCT04794621) supported by the U.S. Department of Defense. It was largely assembled by hand. More than 600 units have been produced with our Ohio manufacturing partner.

​

Gen 2 · In development

Gen 2 keeps the platform’s core principle in a layered design built for production rather than hand assembly. The design was completed in 2026 with our Ohio contract manufacturing partner (The Fischer Group). Gen 2 is our scalable, manufacturable design and will be built in both three-volt and six-volt configurations. Gen 2 has not been studied in patients. Clinical results to date come from Gen 1 and may not apply to Gen 2.

​

In laboratory bench testing at the University of Pittsburgh (a 3 mm-depth agar assay), the six-volt Gen 2 configuration performed equivalently to Gen 1. This was a laboratory experiment; it is not evidence of safety or effectiveness in people.

​

Gen 2 design and manufacturing development was supported by the State of Ohio through the Ohio Department of Development and Ohio Third Frontier, under a Technology Validation and Start-up Fund (TVSF) Phase 2 grant. This content reflects the views of Pavaka Wound Care and does not purport to reflect the views of the Ohio Department of Development or the State of Ohio.

gen2_clean.png

Gen 2 manufacturing-oriented design. Gen 2 has not been studied in patients.

Path to FDA clearance

Pavaka is pursuing two regulatory paths, both built on its scalable, manufacturable Gen 2 design. The three-volt configuration is on a 510(k) pathway; a pre-submission meeting with the FDA is the next step. The six-volt configuration, matching the voltage used in the 112-patient randomized study, is planned for a De Novo pathway seeking a biofilm-related indication. Both configurations are investigational and have not been cleared or approved by the U.S. FDA.

An exclusive license from The Ohio State University

Pavaka holds an exclusive license from The Ohio State University, with no field-of-use restrictions, covering one issued U.S. patent (No. 12,102,508), a second U.S. application allowed by the USPTO (final processing pending), and two additional provisional applications on file. The license was announced in January 2025.

​

The issued patent and the allowed application are owned by the Ohio State Innovation Foundation and licensed exclusively to Pavaka. The inventors are part of the Ohio State team, led by Mechanical and Aerospace Engineering Professor Shaurya Prakash, that developed the platform.

​

Issued patent and allowed application

​

Issued — U.S. Patent No. 12,102,508 B2

“Antimicrobial Wound Care Dressing.” Issued October 1, 2024. Assignee: Ohio State Innovation Foundation. Exclusively licensed to Pavaka Wound Care. View on Google Patents

​

Allowed — U.S. Application No. 18/819,379

“Antimicrobial Wound Care Dressing.” Notice of Allowance issued August 11, 2026; issuance pending. Owned by the Ohio State Innovation Foundation and exclusively licensed to Pavaka.

​

Continuing innovation

​

Pavaka has filed two U.S. provisional patent applications of its own covering next-generation dressing designs. Provisional applications are not published by the USPTO, so details are not shared here. We do not publish license terms.

Where the platform is headed

Our first market focus is orthopedic and foot-and-ankle (podiatry) surgical sites, followed by infected chronic wounds and burns. Research programs include a surgical incision site dressing, layered dressings (including use alongside negative pressure wound therapy), a fungal infections device and a trauma dressing concept for prolonged field care. These programs are investigational or in research.

 

See the pipeline →

Development status

Development status

A qualitative view of development, not a clinical scorecard or a forecast of FDA authorization. Each program is at its own stage, and Gen 1 clinical research is separate from Gen 2 design work.

pipeline-timeline-full-v5.png

Electroceutical wound dressing (Stage 4 of 6). Surgical incision site dressing (Stage 1 of 6). Layered dressing with collagen/fiber/foam/NPWT (Stage 1 of 6). Fungal infections device (Stage 1 of 6).

As of November 2026. Investigational and research programs; none is cleared or approved by the U.S. FDA or available for sale.

Layered dressings

Pavaka is exploring pairing its electroceutical layer with collagen, fiber, foam and NPWT dressings so a clinician could add a low-level electric field at the wound surface without changing the dressing format they already choose. Research and concept stage only; investigational; not studied in patients; not cleared or approved by the U.S. FDA.

Questions worth exploring together

We welcome non-confidential conversations with clinicians, researchers, investors and potential partners.

bottom of page